Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement

Firm News  |  May 21, 2026

---

Gibson Dunn is advising Mentari Therapeutics, Inc. on its merger with InMed Pharmaceuticals, Inc. and concurrent $290 million private placement.

The Gibson Dunn corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.